Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma A Randomized Clinical Trial

Review Oncology

Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy

Gary Ng et al.

Summary: Immunotherapy and targeted therapy have improved outcomes for melanoma patients, but there is a need for further research to guide clinical decisions regarding relapse.

CURRENT ONCOLOGY REPORTS (2022)

添加到收藏夹

Article Oncology

Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective

Egle Ramelyte et al.

Summary: The study found that intralesional T-VEC treatment in primary cutaneous B cell lymphoma patients led to significant tumor response, rapid eradication of malignant cells, activation of the interferon pathway, and early influx of various immune cells, ultimately resulting in enhanced cellular immunity.

CANCER CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial

R. Dummer et al.

Summary: The study found that intralesional injection of an oncolytic virus prior to surgery is clinically beneficial for patients with locally advanced, resectable melanoma, leading to improved recurrence-free survival.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Alexander M. Menzies et al.

Summary: A pooled analysis of neoadjuvant immunotherapy trials in melanoma revealed that the degree of pathological response is correlated with patient survival, serving as a potential surrogate marker for long-term outcomes. Patients with pathological complete response (pCR) after immunotherapy showed significantly improved recurrence-free survival (RFS) and overall survival (OS) compared to those without pCR. Pathological response, particularly pCR, could be an early surrogate endpoint for clinical trials and a new benchmark for development and approval in melanoma.

NATURE MEDICINE (2021)

添加到收藏夹

Review Oncology

The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care

Emily Z. Keung et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2018)

添加到收藏夹

Article Oncology

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H. I. Andtbacka et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma A Randomized Clinical Trial

相关参考文献

Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy

Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

导出引文

分享论文